Corcept Therapeutics Incorporat (CORT) Stock Analysis
Healthcare · Biotechnology
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the... Read more
TrendMatrix rates Corcept Therapeutics Incorporat (CORT) as Hold with high confidence. The stock trades at $41.40 with +37.4% upside to the $55.59 price target. Overall score: 6.6/10 across 10 analysis dimensions. Reward/risk ratio: 1.6:1.
Passes 3/5 gates (positive momentum, clean insider activity, no SEC red flags). Fails on favorable risk/reward ratio. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Corcept Therapeutics Incorporat (CORT) as Hold with high confidence. Score 6.6/10.
Take-profit target: $55.59 (+37.4% upside). Reward/risk ratio: 1.6:1. Stop-loss: $30.86.
Below 200-day MA.
Corcept Therapeutics Incorporat trades at a P/E of 41.3 (forward 21.0). TrendMatrix value score: 7.0/10. Verdict: Hold.
12 analysts cover CORT with a consensus score of 3.8/5. Average price target: $65.
What does Corcept Therapeutics Incorporat do?Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications...
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.